Patents by Inventor Kana Kon-I
Kana Kon-I has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8084476Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: February 10, 2009Date of Patent: December 27, 2011Assignee: Raqualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Patent number: 7700618Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asType: GrantFiled: February 23, 2007Date of Patent: April 20, 2010Assignee: Pfizer IncInventors: Tomoki Kato, Kana Kon-I, Yohei Yuki, Kazuo Ando
-
Patent number: 7598393Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity.Type: GrantFiled: November 2, 2005Date of Patent: October 6, 2009Assignee: Pfizer Inc.Inventors: Kana Kon-I, Miyako Matsumizu, Akiko Shima
-
Publication number: 20090163558Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: February 10, 2009Publication date: June 25, 2009Applicant: RaQualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Publication number: 20090137584Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asType: ApplicationFiled: February 23, 2007Publication date: May 28, 2009Inventors: Tomoki Kato, Kana Kon-I, Yohei Yuki, Kazuo Ando
-
Patent number: 7534914Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: April 29, 2005Date of Patent: May 19, 2009Assignee: ReQualia Pharma Inc.Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Publication number: 20060094750Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma,Type: ApplicationFiled: November 2, 2005Publication date: May 4, 2006Inventors: Kana Kon-I, Miyako Matsumizu, Akiko Shima
-
Patent number: 7012080Abstract: This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a methyl group or an ethyl group; R3 represents a branched alkyl group having from 3 to 6 carbon atoms or an alkyl group having from 3 to 6 carbon atoms substituted by an alkoxy group having from 1 to 6 carbon atoms; with the proviso that when the terminal carbon atom of said alkyl group of R3 is substituted by said alkoxy group, said alkyl group is a branched alkyl group. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: September 17, 2003Date of Patent: March 14, 2006Assignee: Pfizer Inc.Inventors: Satoru Iguchi, Yasuhiro Katsu, Kana Kon-I, Hirohide Noguchi, Chikara Uchida
-
Publication number: 20050267170Abstract: This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions mediated by prostaglandin such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: April 29, 2005Publication date: December 1, 2005Inventors: Hiroki Koike, Kana Kon-i, Yukari Matsumoto, Kazunari Nakao, Yoshiyuki Okumura, Tatsuya Yamagishi
-
Patent number: 6951867Abstract: This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt, amide or ester thereof, wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of R3 is substituted by at least one substituent selected from the group consisting of substituents ?; said substituents ? is aryl, hydroxy, oxo, etc.Type: GrantFiled: September 17, 2003Date of Patent: October 4, 2005Assignee: Pfizer Inc.Inventors: Yasuhiro Katsu, Kana Kon-I, Mikio Morita, Hirohide Noguchi, Chikara Uchida
-
Publication number: 20040127514Abstract: This invention provides a compound of the formula (I): 1Type: ApplicationFiled: September 17, 2003Publication date: July 1, 2004Applicant: Pfizer IncInventors: Yasuhiro Katsu, Kana Kon-I, Mikio Morita, Hirohide Noguchi, Chikara Uchida
-
Publication number: 20040122043Abstract: This invention provides a compound of the formula (I): 1Type: ApplicationFiled: September 17, 2003Publication date: June 24, 2004Applicant: Pfizer IncInventors: Satoru Iguchi, Yasuhiro Katsu, Kana Kon-I, Hirohide Noguchi, Chikara Uchida